Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 09, 2008. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding changes in shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific insider transaction rather than a financial performance report.
Material Changes
The only material change disclosed is an increase in the shareholding of Mr. C. Viehbacher. On July 09, 2008, his interest in Ordinary share ADRs increased following the notional re-investment of dividends. The transaction occurred at a price of $44.11 per ADR, relating to a one-off conditional award received on February 19, 2008. The specific number of shares involved is listed as 1,459.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of director transactions.
Investor Verification Points
- Verify the total shareholding of Mr. C. Viehbacher post-transaction to assess concentration of ownership.
- Confirm the terms of the one-off conditional award granted on February 19, 2008, to understand the vesting schedule and conditions.
- Review the company's broader insider trading activity for the same period to identify any patterns.